Why Is Sonnet BioTherapeutics Stock Trading Higher On Monday?

Benzinga·07/14/2025 15:30:07

Listen to the news

Sonnet BioTherapeutics Inc. (NASDAQ:SONN) stock surged Monday amid high trading volume following news of a transformative business combination with Rorschach I, backed by Atlas Merchant Capital and Paradigm.

The deal will create Hyperliquid Strategies Inc., a public cryptocurrency treasury company holding around 12.6 million HYPE tokens—worth $583 million—plus $305 million in cash, for a total assumed value of $888 million.

The new entity will remain Nasdaq-listed under a new ticker and be led by Bob Diamond (Chairman) and David Schamis (CEO). Major crypto investors including Galaxy Digital, Pantera Capital, and D1 Capital are participating. Sonnet will become a subsidiary of Hyperliquid Strategies, continue biotech R&D (e.g., SON-1010), and raise $5.5 million via private placement.

Shareholders will receive a contingent value right (CVR) tied to Sonnet's legacy biotech assets, which remain open to partnership deals.

In April, Sonnet BioTherapeutics released safety results of SON-1010 (IL12-FHAB) at the highest dose combined with atezolizumab in the Phase 1b/2a trial in adult patients with advanced solid tumors or platinum-resistant ovarian cancer (the SB221 study).

Based on feedback from a formal evaluation by the Safety Review Committee (SRC) for the SB221 study, the study can now advance to the expansion phase.

This phase will study the preliminary effect of the combination at the MTD before proceeding to a Phase 2a randomized comparison with the standard of care.

Price Action: SONN stock is up 151% at $12.98 at the last check on Monday.

Read Next:

Nokia Adds New Developer Tools On Google Cloud Marketplace

FAQ

Fee Schedule Open Account Deposit & Withdrawal Trading

Terms & Conditions

Client Agreement Privacy Policy Data Disclaimer Security Tips

About Webull

About us Webull Promotions Contact information Announcements

Service Email : service@webull.hkBusiness Cooperation : marketinghk@webull.hk

Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.

Language

English